Sun's buyout of Ranbaxy gets India's approval

India's high court has waived a waiting period for Sun Pharmaceutical to complete its $4 billion acquisition of Ranbaxy Laboratories. The merger is expected to be completed soon, which will set into motion Sun's pledge to reform manufacturing at Ranbaxy. Four of Ranbaxy's FDA-approved manufacturing facilities in India are banned from shipping to the U.S. market because of data integrity and quality issues. Story | More

Suggested Articles

Gilead expects to sell 1 million to 1.5 million treatment courses of remdesivir in 2020. That means about $3.5 billion in sales, one analsyt figures.

Pfizer and BioNTech followed supply pacts in the U.S. and U.K. with a new deal to deliver 120 million vaccines to Japan in the first half of 2021.

Warp Speed's largest outlay to date, the funding will cover development and manufacturing scale-up of a vaccine that uses proven Sanofi technology.